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Stilbenes are a class of polyphenolic compounds, naturally found in a wide variety of di-
etary sources such as grapes, berries, peanuts, red wine, and some medicinal plants. There
are several well-known stilbenes including trans-resveratrol, pterostilbene, and 30-
hydroxypterostilbene. The core chemical structure of stilbene compounds is 1,2-
diphenylethylene. Recently, stilbenes have attracted extensive attention and interest due
to their wide range of health-beneficial effects such as anti-inflammation, -carcinogenic,
-diabetes, and -dyslipidemia activities. Moreover, accumulating in vitro and in vivo studies
have reported that stilbene compounds act as inducers of multiple cell-death pathways
such as apoptosis, cell cycle arrest, and autophagy for chemopreventive and chemother-
apeutic agents in several types of cancer cells. The aim of this review is to highlight recent
molecular findings and biological actions of trans-resveratrol, pterostilbene, and 30-
hydroxypterostilbene.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The natural active compounds from plant or herbal origins are
being investigated for their bioactivities [1]. Stilbenes are
phytochemicals with ~200e300 g/mol molecular weight, a
subclass of polyphenolic compounds [2]. They are naturally
found in a wide variety of dietary sources such as grapes,
blueberries, red wine, and some other plants [3e5]. Familytment of Food Science, R
National Pingtung Unive
(C.-T. Ho), chenyk@mail.n
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).members of the stilbene have a C6-C2-C6 basic skeleton and
consist of two phenyl groups linked by an ethene double bond.
There are several well-known stilbenes such as trans-resver-
atrol, pterostilbene, and 30-hydroxypterostilbene (Figure 1).
Resveratrol (3,40,5-trihydroxy-trans-stilbene) is the most
extensively studied stilbene found in grape skin, berries,
peanuts, and some medicinal plants [3,4,6]. Hundreds of
studies have shown that resveratrol plays a critical role in
human health and diseases due to its diverse biological andutgers University, 65 Dudley Road, New Brunswick, NJ 08901, USA;
rsity of Science and Technology, 1 Shuefu Road, Pingtung 91201,
pust.edu.tw (Y.-K. Chen).
hed by Elsevier Taiwan LLC. This is an open access article under the CC
Figure 1 e Chemical structures of (A) resveratrol, (B)
pterostilbene, and (C) 3′-hydroxypterostilbene.
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tion, -carcinogenic, and -diabetic potencies [7e13]. However,
one potential issue surrounding resveratrol is that resveratrol
has a very low bioavailability that may lower its biological
effectiveness [14e16].
Pterostilbene, the 3,5-dimethoxymotif at the A-phenyl ring
of resveratrol, has recently received tremendous attention
due to its promising chemopreventive and chemotherapeutic
properties [17e26]. Due to its structural characteristic, pter-
ostilbene ismore lipophilic, exhibits better bioavailability, and
is more biologically active than resveratrol [16]. Pterostilbene
is primarily found in a tree wood, Pterocarpus marsupium,
which is a traditional herbal medicine used for the treatment
of diabetes [27]. Moreover, in recent studies, pterostilbene
have been reported to have powerful growth-inhibitory effects
in several different types of cancer cells, notably breast, colon,
and prostate cancer cells. [18,25,28]. In multiple research
findings, pterostilbene was shown to be an effective apoptotic
and autophagic agent that is able to inhibit cancer cell
viability, induce cell cycle arrest, alter apoptosis expression
gene, promote autophagy-related proteins, and inhibit cancer
cells from metastasizing [18,25,28,29].
30-Hydroxypterostilbene (trans-3,5-dimethoxy-30,40-dihy-
droxystilbene), one of metabolites of pterostilbene [30], can
also be isolated from whole plant of the herb Sphaerophysa
salsula, a shrub widely distributed in central Asia and north-
west China [20,31]. The latest researches showed that 30-
hydroxypterostilbene appeared to contribute stronger bio-
logical activities than pterostilbene on human colon cancer
cells [28].
This article reviews the recent advances in understanding
the biological activities, molecular effects, and bioavailability
of resveratrol, pterostilbene, and 30-hydroxypterostilbene, and
summarizes their clinical potential for the prevention and
treatment of chronic diseases.2. Resveratrol
Resveratrol (trans-3,5,40-trihydroxystilbene), is a natural
polyphenolic phytoalexin compound produced by plants toprotect them from injury, uv irradiation, and fungal attack
[32,33]. It is one of well-studied stilbenes mainly found in
grapes and red wine; however, the presence of resveratrol has
also been detected in other plants such as peanuts, pistachios,
and berries [3,4,34]. In the past few years, the interest in
resveratrol has extensively increased and a lot of scientific
evidence has demonstrated that resveratrol exerts a plethora
of biological functions, especially in the protective effects of
chronic diseases, such as anti-inflammation, -cancer, -dia-
betes, and -obesity activities [7e10,12] (Table 1).
2.1. Inflammation
Chronic inflammation has been recognized as the root cause
of various human diseases. The inflammatory processes may
induce DNA mutations in cells via oxidative or nitrosative
stress, which may influence normal cell functions and
consequently lead to inflammatory diseases and cancer [35].
In an experiment conducted by Cui et al [36], it was demon-
strated that resveratrol significantly suppressed inflammation
markers such as inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), and tumor necrosis factor-a (TNF-
a) in dextran sulfate sodium (DSS) mouse model of colitis. In
addition, resveratrol inhibited neutrophils infiltration in the
mesenteric lymph nodes and lamina propria, and decreased
the numbers of CD3þ T cells that express TNF-a and interferon
gamma (IFN-g) in DSS-treated mice [36]. Sanchez-Fidalgo and
co-workers [37] also found similar results. In their study using
DSS-induced colitis model, it was determined that resveratrol
supplementation attenuated chronic colonic inflammation
with reduced proinflammatory cytokines, including
interleukin-1 beta (IL-1b), IL-10, prostaglandin E synthases-1
(PGES-1), TNF-a, iNOS, and COX-2, via downregulation of the
p38 MAPK (mitogen-activated protein kinases) signaling
pathway [37].
Recently, the study performed by Lee et al [9] suggested
that resveratrol could increase the bioavailability of apigenin,
which is a bioactive flavonoid with strong anti-inflammation
activities. Cotreatment of apigenin and resveratrol increased
the levels of plasma apigenin up to 2.39 times compared to the
apigenin-alone group. Moreover, cotreatment of apigenin and
resveratrol significantly reduced the paw edema caused by
carrageenan-induced inflammation in mice. These findings
indicated that resveratrol could act as a biological enhancer to
strengthen the anti-inflammatory activity of apigenin [9].
2.2. Breast cancer
A number of researchers have considered the anticarcino-
genic effects of resveratrol in breast cancer [38e40]. A study
conducted by Scarlatti et al [38] reported that resveratrol could
inhibit human breast cancer cell proliferation and promote
death via multiple pathways including apoptosis, cell cycle
arrest in the S phase, and autophagy. Resveratrol was shown
to induce cell death in both caspase-3 sensitive (MCF-7casp-3)
and caspase-3 insensitive (MCF-7vc) human breast cancer
cells. Thus, the effects of resveratrol on breast cancer cell
deathmight not be fully dependent on caspase-3 [38]. Besides,
resveratrol stimulated autophagy by activating noncanonical
(Beclin-1 independent) routes in both cell lines. Themolecular
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associated with the suppression of Akt/protein kinase B (PKB)
phosphorylation and mammalian target of rapamycin
(mTOR)/S6K signaling pathway [38]. In another study, He et al
[39] found that resveratrol and rapamycin combination might
be a novel combinatorial strategy for breast cancer therapy.
The findings of this study indicated that resveratrol signifi-
cantly potentiate the anticancer activity of mTOR inhibitor
rapamycin by suppressing rapamycin-induced AKt signaling
pathway in MDA-MB-231, MCF-7, and BT-549 human breast
cancer cells [39].
2.3. Prostate cancer
Prostate cancer epithelial cells possess large amounts of cal-
cium channels that mediate multiple cellular processes such
as cell proliferation, tumorigenesis, and migration [41,42].
Thus, modulation of calcium homeostasis seems to play an
important role in the treatment of prostate cancer. In a recent
study, Selvaraj et al [43] found that resveratrol could inhibit
cell proliferation and survival of prostate cancer PC-3 and
DU145 cells via downregulation of stromal interaction mo-
lecular 1 (STIM1) which acts as calcium sensor in endoplasmic
reticulum (ER). Resveratrol treatment reduced the expression
of STIM1, thereby, inhibiting the interaction of STIM1 and
transient receptor potential channel 1 (TRPC1), which could
attenuate Ca2þ entry and induce prostate cancer cell death
[43]. In addition, resveratrol treatment also induced ER stress
by decreasing ER calcium storage and storing operated cal-
cium entry (SOCE). Moreover, resveratrol was shown to induce
autophagic cell death via activation of AMP-activated protein
kinase (AMPK) and inhibition of Akt/mTOR pathway [43].
Another study conducted by Sheth et al [44] in 2012
determined the chemopreventive properties of resveratrol in
androgen insensitive and highly aggressive human prostate
cancer cells, PC-3M-MM2. The results showed that resveratrol
negatively regulated prostate cancer cell proliferation by
inducing apoptosis. Resveratrol treatment substantially
inhibited PC-3M-MM2 cell invasion and migration in Boyden
chamber invasion and wound healing assays. Also, resvera-
trol enhanced tumor suppressor proteins, maspin, and pro-
grammed cell death 4 (PDCD4) expressions, via
downregulation Akt /MicroRNA-21 (MiR-21) signaling pathway
[44].
To further understand the antitumor efficacy of resveratrol
in vivo, Sheth et al [44] performed a study in a PC-3M-MM2
xenograft-severe combined immunodeficient (SCID) mouse
model. The findings showed that resveratrol treatment
(20 mg/kg BW) for 5 weeks caused significant reduction of
prostate tumor growth and the incidence and number of lung
metastasis in SCID mice. The mechanisms involved in these
antitumor and -metastatic effects of resveratrol were inhibi-
tion of Akt/MiR-21 pathway and upregulation of PDCD4 levels
[44].
2.4. Colon cancer
Resveratrol also possesses significant anti-colon cancer ac-
tivity [15,45]. In 2011, Nutakul et al [15] demonstrated that
resveratrol exhibited anti-carcinogenic effects in three humancolorectal carcinoma cells, Caco-2, HCT-116, and HT-29.
Resveratrol was shown to induce apoptosis by activation of
caspase-3 and poly (ADP-ribose) polymerase (PARP). Another
study by Miki et al [45] indicated that resveratrol effectively
induced cytotoxic effects by reactive oxygen species (ROS)-
mediated apoptosis and autophagy in HT-29 and COLO 201
human colon cancer cells. Treated HT-29 and COLO 201 cells
with resveratrol could trigger apoptosis via increasing the
levels of caspase-8, -3, and PARP but have no effect on Bax and
Bcl-xL levels. Thus, the proposed mechanisms involved
resveratrol-induced apoptosis might undergo caspase-8/-3
activation. Besides, resveratrol was found to cause autopha-
gic cell death by upregulating LC3 II protein level and increase
the autophagosome formation in HT-29 and COLO 201 cells
[45]. Moreover, resveratrol-induced apoptosis and autophagy
aremediated by intracellular ROS production. Elevated level of
ROS is associated with increased caspase-8 and -3 cleavage
and LC3 II expression [45]. Therefore, the combination of
resveratrol with ROS inducer might be useful for colon cancer
treatment.
In vivo studies, Cui et al [36] demonstrated that resveratrol
significantly suppressed the development of colon cancer. In
azoxymethane (AOM)/DSS-induced colon cancer model,
resveratrol effectively lowers the incidence of colon tumors.
The tumor incidence in AOM/DSS-treated mice was 80%
whereas only 20% of mice treated with AOM þ DSS þ resver-
atrol had tumor incidence [36]. Likewise, resveratrol treat-
ment greatly decreased the tumor multiplicity (number of
tumors per animal). AOM/DSS-treated mice had an average
tumor multiplicity of 2.4 ± 0.7 while AOM þ DSS þ resveratrol
group only had 0.2 ± 0.13 tumors per mouse. Thus, resveratrol
showed great potential as a useful agent for the treatment of
colon cancer.2.5. Diabetes mellitus
Resveratrol has been reported to have beneficial effects in
diabetes and diabetic vascular complication [7,8,46,47].
Studies on rodent models of diabetes have suggested that
chronic resveratrol administration potentiates improving
hyperglycemia, glucose tolerance, and dyslipidemia and pro-
tecting against pancreatic b-cell failure as well as diabetic
cardiomyopathy [11,12,47]. In 2012, Do et al [47] conducted a
study using C57BL/KsJ-db/db mice fed with resveratrol (0.02%
w/w) for 6 weeks. Treatment with resveratrol significantly
reduced the fasting blood glucose and hemoglobin A1c, which
has a similar hypoglycemic effect as an antidiabetic drug,
rosiglitazone [47]. Moreover, resveratrol effectively sup-
pressed the expression of hepatic gluconeogenic enzymes,
phosphoenolpyruvate carboxykinase (PEPCK), and glucose 6-
phosphate (G6P), while increased the hepatic glycolytic gene
expression, pyruvate kinase (PK), and sterol regulatory
element binding protein 1c (SREBP1c) leading to decrease
glycogen synthesis in liver. The dyslipidemia, free fatty acid,
triacylglycerol, and ApoB/ApoAI levels were also regulated
through enhancing AMPK activity [47]. Similarly, in 2015 Yao
et al [7] found that resveratrol ameliorated gestational dia-
betes mellitus symptoms via activation of AMPK. Supple-
mentation of resveratrol effectively improved glycemic
Table 1 e The biological activities and molecular effects of trans-resveratrol.
Modes/treatments Model used Mechanism References
Inflammation
Resveratrol mixed in AIN-93 diet (300 ppm) DSS-induced colitis C57BL/6 mice YiNOS, YCOX-2, YTNF-a, Y% of neutrophils inmesenteric lymph nodes
& lamina propria, YCD3þ T-cell counts
Cui et al, 2010 [36]
Resveratrol (3 mg/kg BW) DSS-induced colitis C57BL/6 mice YDisease activity index, [weight/length of the colon, YHistological
signs of cell damage
YTNF-a, YIL-1b, YIL-10, YiNOS, YPGES-1, YCOX-2, Yp-p38,
Sanchez-Fidalgo
et al, 2010 [37]
Resveratrol (10e40mM) RAW 264.7 YNO, YPGE2, YiNOS, YCOX-2, YIL-1b, YIL-6, YTNF-a, Lee et al, 2015 [9]
Co-administration of resveratrol (25mg/kg) & apigenin
(50 mg/kg)
Carrageenan-induced
paw edema in mice
YEdema, [Apigenin bioavailability, Yapigenin glucuronides Lee et al, 2015 [9]
Breast cancer
Resveratrol (16e64mM) MCF-7casp-3
(caspase sensitive)
YCell viability, [Fragmented & condensed nuclei, [caspase-3/7, [PARP
cleavage, [ autophagosome, [LC3II, YAkt/PKB
phosphorylation,Yp70S6K phosphorylation
Scarlatti et al, 2008 [38]
Resveratrol (16e64mM) MCF-7vc
(caspase insensitive)
YCell viability, [Fragmented & condensed nuclei, [autophagosome,
[LC3II, YAkt/PKB phosphorylation, Yp70S6K phosphorylation
Scarlatti et al, 2008 [38]
Resveratrol (10e50mM) MDA-MB-231, MCF-7, & BT-549 YCell viability, [rapamycin sensitivity, [apoptosis, [cell cycle arrest,
YAkt phosphorylation
He et al, 2011 [39]
Prostate cancer
Resveratrol (5e100mM) PC-3-M-MM2 YCell viability, [apoptosis, [TUNEL, Ycell migration (wound healing
assay), Ycell invasion (Boyden chamber invasion assay), YmiR-21,
[maspin, [PDCD4, YAkt phosphorylation
Sheth et al, 2012 [44]
Resveratrol (20 mg/kg BW) PC-3M-MM2 xenograft SCID mice YTumor volume, Ytumor weight, Ylung metastasis, YAkt
phosphorylation, YmiR-21, [PDCD4
Sheth et al, 2012 [44]
Resveratrol (25e100mM) PC-3 & DU145 YCell viability, YSTIM1, YSTIM1-TRPC1, Ystore-mediated Ca2þ entry,
[LC3B-II, [GFP-LC3B, [GRP78, [CHOP, Yp-mTOR, [p-AMPK, Yp-
p70S6K
Selvaraj et al, 2015 [43]
Colon cancer
Resveratrol mixed in AIN-93 diet (300 ppm) AOM/DSS-induced colonic
carcinogenesis C57BL/6 mice
YColon tumor incidence, Ytumor multiplicity, Ytumor volume Cui et al, 2010 [36]
Resveratrol (5e100mM) HCT-116, HT-29, & Caco-2 YCell viability, Ycolony formation capacity, [apoptosis, [caspase-3,
[PARP
Nutakul et al, 2011 [15]
Resveratrol (25e150mM) HT-29 & COLO 201 YCell viability, Ycolony formation capacity, [apoptosis, [caspase-3,
[caspase-8, [PARP, [autophagy, [LC3B-II, [autophagosome, [ROS
production
Miki et al, 2012 [45]
Diabetes
Resveratrol (0.02% w/w) C57BL/KsJ-db/db mice YBlood glucose, Yfree fatty acid, Ytriglyceride, YApoB/Apo AI,
[adiponectin, Yhemoglobin A1c, YPEPCK, YG6P, [GK, [SREBP, Yhepatic
glycogen, Y hepatic triglyceride, [pancreatic insulin protein, [insulin,
[GLUT4, [p-AMPK, [uncoupling protein
Do et al, 2012 [47]
Resveratrol (250 mg/d) Patients with type II diabetes YHemoglobin A1c, Ysystolic blood pressure Bhatt et al, 2012 [46]
Resveratrol (5 mg/kg/d) Streptozotocin-nicotinamide
induced type II diabetes rats
[Glucose tolerance, [pancreatic insulin, [Cardiac antioxidant
enzymes activities, [catalase, [superoxide peroxidase, Ynitrate/
nitrate, Y8-isoprostane, YNF-kB
Mohammadshahi
et al, 2014 [12]
(continued on next page)
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Table 1 e (continued )
Modes/treatments Model used Mechanism References
Resveratrol (10 mg/kg BW) C57BL/KsJ-Lepdb/þ [Glucose metabolism, [insulin tolerance, [pAMPK, YpHDAC4,
YG6Pase, [reproductive outcome
Yao et al, 2015 [7]
Obesity
Resveratrol (0.4%) High-fat diet-induced obese mice YBody weight gain, Yepididymal adipose tissue, Yperirenal adipose
tissue, Ymesenteric adipose tissue, Yretroperitoneal adipose tissue,
Ytriglyceride, Yfree fatty acid, Yglucose, YHOMA-IR, YTNF-a, YMCP-1,
YGalR1, YGalR2, YPKCd, YCyc-D, YE2F1, YPPARg, YC/EBPa, YSREBP1c,
YLXR, YFAS, YLPL, YaP2, YLeptin, Yp-ERK
Kim et al, 2011 [48]
Resveratrol (150 mg/d) Healthy obese men (BMI 28e36 kg/m2) YAdipocyte diameter, Ythe proportions of very-large adipocytes (>
90mM), Ythe proportions of large adipocytes (70e89mM), [the
proportions of small adipocytes (< 50mM), YWnt signaling pathway,
YNotch signaling pathway, [lysosomal pathways, [phagosomal
pathway
Konings et al, 2014 [13]
Resveratrol (0.03e10mM) 3T3-L1 adipocyte YAdipogenesis, YPPARg, Yperilipin, Ylipolysis Chang et al, 2016 [10]
Resveratrol (1-, 10-, 30-mg/kg BW) High-fat diet-induced obese mice YBody weight gain, Ysubcutaneous adipose tissue, Yepididymal
adipose tissue, Yfat droplet accumulations
Chang et al, 2016 [10]
Aging
Resveratrol (2.5e10mM) Saccharomyces cerevisiae [Sir2, [lifespan Howitz et al, 2003 [51]
Resveratrol (6.25e100mM) Drosophila melanogaster &
Caenorhabditis elegans
[Sir2, [lifespan Wood et al, 2004 [52]
Resveratrol (22.4 mg/kg BW) Mice on a high-calorie diet [Lifespan, [insulin sensitivity, YIGF-1, [AMPK, [PGC-1a,
[mitochondrial number, [motor function
Baur et al, 2006, [55]
Resveratrol (100-, 400- & 2400-mg/kg food) Elderly mice (12-mo-old) [Insulin sensitivity, [cardiovascular function, [bone density, [motor
coordination, Yinflammation, Yvascular endothelium apoptosis,
Ycataract formation
Pearson et al, 2008 [56]
Resveratrol (30mM & 130mM) Honey bees [Lifespan, Ythe food consumption Rascon et al, 2012 [54]
Resveratrol (0.05mM, 0.5mM, & 1mM) D. melanogaster [Lifespan, [stress resistance, Yage-dependent decline of locomotor
activity
Danilov et al, 2015 [57]
Resveratrol (200 mg/g diet) Annual fish Nothobranchius guentheri YROS, [CAT, [SOD, [GPx, Ycarbonyl contents, YMDA, Ylipofuscin Liu et al, 2015 [59]
Resveratrol (20 mg/kg BW) Aged rats (18-mo-old) [The dendritic length & spine density in pyramidal neurons of
prefrontal cortex, dorsal hippocampus, & dentate gyrus
Hernandez-Hernandez
et al, 2016 [58]
ApoAI ¼ Apolipoprotein AI; ApoB ¼ Apolipoprotein B; CAT ¼ catalase; CD3þ T-cell ¼ cluster of differentiation 3þ T-cell; C/EBPa ¼ CCAAT-enhancer-binding protein alpha; COX-2 ¼ cyclooxygenase-2;
Cyc-D ¼ cyclin-D; FAS ¼ fatty acid synthase; G6P ¼ glucose-6 phosphate; G6Pase ¼ glucose-6 phosphatase; GalR1 ¼ galanin receptor R1; GalR2 ¼ galanin receptor R2; GFP-LC3B ¼ green fluorescent
protein-microtubule-associated protein 1 light chain 3 beta; GK ¼ glucokinase; GLUT4 ¼ glucose transporter 4; GPx ¼ glutathione peroxidase; GRP78 ¼ 78 kDa glucose-regulated protein; HOMA-IR ¼
homeostatic model assessment-insulin resistance; IGF-1 ¼ insulin-like growth factor-1; IL-1b ¼ interleukin 1 beta; IL-6 ¼ interleukin 6; IL-10 ¼ interleukin 10; iNOS ¼ inducible nitric oxide synthase;
LC3 II ¼ autophagy-related protein light chain 3 II; LPL ¼ lipoprotein lipase; LXR ¼ liver X receptor; MCP-1 ¼monocyte chemoattractant protein-1; MDA ¼malondialdehyde; miR-21 ¼microRNA-21;
NF-kB ¼ nuclear factor kappa B; NO ¼ nitric oxide; p70S6K ¼ 70 kDa ribosomal protein S6 kinase; p-AMPK ¼ phosphorylated adenosine monophosphate activated protein kinase; PARP ¼ poly ADP-
ribose polymerase; PDCD4 ¼ programmed cell death 4; PEPCK ¼ phosphoenolpyruvate carboxykinase; p-ERK ¼ phosphorylated extracellular signal-related kinase; PGC-1a ¼ peroxisome proliferator-
activated receptor gamma coactivator 1-alpha; PGE2 ¼ prostaglandin E2; PGES-1 ¼ prostaglandin E synthases-1; pHDAC4 ¼ phospho-histone deacetylase 4; PKB ¼ protein kinase B; PKCd ¼ protein
kinase C delta; p-mTOR ¼ phosphor-mammalian target of rapamycin; p-p38 ¼ phopho-p38; PPARa ¼ peroxisome proliferator activated receptor alpha; PPARg ¼ peroxisome proliferator activated
receptor gamma; Sir2¼ sirtuin 2; SOD¼ superoxide dismutase; ROS ¼ reactive oxygen species; SREBP ¼ sterol regulatory element-binding protein; TNF-a¼ tumor necrosis factor-a; TRPC1 ¼ transient
receptor potential cation channel subfamily C member 1; TUNEL ¼ terminal deoxynucleotidyl transferase dUTP nick end labeling.
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pregnant C57BL/KsJ-Lepdb/þ mice.
In a recent clinical study, 62 patients with type II diabetes
were oral supplementation with resveratrol (250 mg/d) for 3
months. The results showed that treatment with resveratrol
significantly reduced the hemoglobin A1c and systolic blood
pressure in type II diabetic patients [46]. These findings
demonstrated that dietary resveratrol might have promising
protective effects of diabetes.
2.6. Obesity
Resveratrol has potential as an antiobesity agent via down-
regulation of adipogenic processes [10,48]. A study conducted
by Chang et al [10] showed that resveratrol suppressed adi-
pogenic differentiation in 3T3-L1 cells by downregulating both
peroxisome proliferator-activated receptor gamma (PPARg)
and perilipin proteins expression, which are two key regula-
tors of adipogenesis and lipogenesis. Additionally, in order to
better understand the antiobese effects in vivo, the authors
performed an experiment using a high-fat diet (HFD)-induce
obese mice model. Administration of resveratrol (1e30 mg/kg
BW) for 10 weeks significantly reduced body weight gain in a
dose-dependent manner [10]. Also, resveratrol significantly
decreased the weight of subcutaneous and epididymal adi-
pose tissues in HFD-treated mice, but had no effect on brown
adipose tissue. Furthermore, it was shown that resveratrol
greatly reduced fat droplet accumulations in adipose tissue.
Similarly, Kim et al [48] reported that resveratrol supplemen-
tation effectively reduced the body weight gain, the weight of
visceral adipose tissues, plasma triacylglycerol, free fatty acid,
glucose, TNF-a, and monocyte chemoattractant protein-1
(MCP-1) via downregulation of galanin-mediated signaling
modulators (GalR1, GalR2, PKCd, Cyc-D, E2F1, and p-ERK) and
adipogenic genes expression (PPARg, C/EBPa, SREBP1c, LXR,
FAS, LPL, aP2, and Leptin) [48].
Recently, a human study by Konings et al [13] investigated
the effects of resveratrol treatment on adipose tissue
morphology and gene expression in healthy obese men.
Eleven healthy obese men with body mass index (BMI) be-
tween 28 kg/m2 and 36 kg/m2 were administrated with pla-
cebo and resveratrol (150 mg/d) for 30 days. The results
showed that resveratrol significantly reduced abdominal
subcutaneous adipocyte size (placebo 74.7 ± 3.5mM; resvera-
trol 65 ± 4.4mM). Resveratrol treatment greatly decreased the
proportion of large (70e89mM) and very-large (> 90mM) adipo-
cytes, while increasing the small adipocytes (< 50mM) pro-
portion [13]. Moreover an interesting finding was observed,
resveratrol activated lysosomal and phagosomal signaling
pathways in obese men which might be an alternative
pathway of lipolysis through lysosome-dependent autophagy
[13].
2.7. Aging
It has been demonstrated that resveratrol possesses the po-
tential of lifespan extension in various organism and animal
models [49,50]. Most reports suggested that themechanism in
regard to longevity promotion by resveratrol is related to cal-
orie restriction. In a study conducted by Howitz et al [51]indicated that resveratrol enhanced DNA stability and pro-
longed 70% lifespan of budding yeast Saccharomyces cerevisiae
by activating Sir2, a member of the sirtuin family induced by
energy restriction, mimicking the effects of calorie restriction.
Furthermore, resveratrol lengthened lifespan through activa-
tion of Sir2 in Drosophila melanogaster and Caenorhabditis ele-
gans [52] aswell as induction of Sirt-1-dependent autophagy in
C. elegans [53]. Thirty micrometres and 130mM of resveratrol
treatments were shown to extend average lifespan of honey
bees by 38% and 33%, respectively, as well as maximum and
median lifespan [54]. They found that resveratrol significantly
decreased food consumption in bees, compared to unsupple-
mented controls, which means that the lifespan extension
effect of resveratrol may be mediated via caloric restriction.
Regarding vertebrates, Baur et al [55] demonstrated that di-
etary resveratrol significantly increased the lifespan of high-
calorie diet-fed mice through improved their physiological
conditions associatedwith health, including enhanced insulin
sensitivity, reduced IGF-I levels, increased AMPK and PGC-1a
activities, elevated mitochondrial number, and improved
motor function. In another study, Pearson et al [56] found that
long-term resveratrol treatment of elderly mice could mimic
transcriptional changes induced by dietary restriction and
showed a marked reduction of diverse signs of aging,
including improved insulin sensitivity, cardiovascular func-
tion, bone density, and motor coordination, and reduced
inflammation, apoptosis in the vascular endothelium, and
cataract formation.
In addition to calorie restriction, other mechanisms for the
anti-aging benefit of resveratrol have also been studied.
Danilov and colleagues [57] investigated the effects of
nonsteroidal anti-inflammatory drugs (NSAIDs), such as
aspirin, valeroyl salicylate, trans-resveratrol, valdecoxib, lico-
felone, on longevity of D. melanogaster. They found that
treatment of D. melanogaster with NSAIDs, including resvera-
trol, caused a prolongation in lifespan. Moreover, resveratrol
delayed age-dependent decline of locomotor activity and
increased stress resistance inD. melanogaster. It was suggested
that the anti-aging effects of NSAIDs in Drosophila model is
mediated by Pkh2-ypk1-lem3-tat2 signaling pathway [57]. A
study conducted by Hernandez-Hernandez et al [58] showed
that daily oral administration of 20 mg/kg bw of resveratrol to
aged rats (18-month-old) for 60 days significantly induced
modification of dendritic morphology in prefrontal cortex,
dorsal hippocampus, and dentate gyrus, and these changes
could explain the therapeutic effect of resveratrol in aging and
in Alzheimer's disease. Furthermore, resveratrol was shown
to lengthen lifespan of annual fish, Nothobranchius guentheri,
and to improve several oxidative stress-related factors,
including reducing the levels of ROS, enhancing the activities
of antioxidant enzymes, and decreasing the degree of oxida-
tive damage, which were induced by aging [59].3. Pterostilbene
Pterostilbene (trans-3,5-dimethoxy-40-hydroxystilbene), natu-
ral dimethylated analogue of resveratrol, is a stilbenoid
phytochemical compound primarily found in blueberries,
grapes, and a tree wood, Pterocarpus marsupium [2,25,31,60].
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Vaccinium ashei (rabbiteye blueberry) contains 99 ng/g dry
sample, while Vaccinium stamineum (deerberry) contains
560 ng/g dry sample [3,61]. Substantial studies demonstrate
that pterostilbene have diverse pharmacological activities for
the prevention and treatment of diseases including inflam-
mation, cancer, diabetes, and dyslipidemia [29,60,62e66]
(Table 2).
3.1. Inflammation
A study conducted by Hsu et al [67] showed that pterostilbene
exhibited strong inflammatory inhibitory effects in 3T3-L1
adipocytes and RAW264.7 macrophages coculture. It showed
that pterostilbene significantly inhibited cytokines IL-6 and
TNF-a secretion and proinflammatory gene expression
including COX-2, iNOS, IL-6, TNF-a, MCP-1, and plasminogen
activator inhibitor-1 (PAI-1) and also decreased the migratory
ability of macrophages toward adipocytes [67]. Further study
was performed by Liu and colleagues [68] evaluating the anti-
inflammation effects of pterostilbene in endothelial HUVECs
cells. Pterostilbene treatment markedly attenuated inflam-
matory responses by reducing the production of cytokines
including soluble intercellular adhesion molecule-1 (sICAM1),
IL-8, MCP-1, and sE-selectin and inhibiting the adhesion of
U937 monocytes to HUVECs cells. Also, pterostilbene
decreased the expression of endoplasmic reticulum stress
(ERS)-related proteins such as, eIF2a, ICAM1, matrix metal-
lopeptidase 9 (MMP9), and GRP78 [68].
3.2. Breast cancer
Pterostilbene has been shown to exhibit anticarcinogenic ac-
tivities in breast cancer [18,69,70]. Chakraborty and colleagues
[69] found that pterostilbene induced cytotoxic effects by
generating reactive oxygen species (ROS) in MCF-7 breast
cancer cells. Treated MCF-7 cells with pterostilbene could
trigger apoptosis via increasing the levels of caspase-3 and
apoptotic protein Bax, and decreasing the antiapoptotic pro-
tein Bcl-2 levels and mitochondrial membrane potential [69].
In 2012, the same research group further demonstrated that
pterostilbene caused autophagy by upregulating the expres-
sion of autophagy-related proteins including Beclin-1 and LC3
II in MCF-7 cells [70]. Furthermore, Wang et al [18] also indi-
cated that pterostilbene could simultaneously stimulate
apoptosis, cell cycle arrest, and autophagy in human breast
cancer MCF-7 and Bcap-37 cells.
3.3. Prostate cancer
In prostate cancer, Wang et al [71] reported that treatment of
p53 wild type human prostate cancer LNCaP cell with 25mM
pterostilbene could inhibit cell viability and induce cell cycle
arrest at G1/S phase by increasing the cyclin-dependent ki-
nase inhibitor CDNK1A and CDNK1B. Furthermore, pter-
ostilbene treatment had strong inhibitory effect on prostate-
specific antigen (PSA) expression. In addition, Chakraborty
et al [69] treated p53 null type human prostate cancer PC-3
cells with pterostilbene and found that pterostilbene
induced apoptosis by increasing the cellular ROS, caspase-3,and apoptotic protein Bax and decreasing antiapoptotic pro-
tein Bcl-2. Pterostilbene also inhibited MMP-9 and a-methyl-
acyl-CoA recemase (AMACR), which are two notable
metastasis activators. Similarly, other studies conducted by
Lin et al [25] in 2012 indicated the same results as previous
studies. Pterostilbene treatment induced differential effects in
p53 positive and negative human prostate cancer cell that
could upregulate cell cycle arrest at G1 phase in LNCaP cells,
while caused the PC-3 cells undergo apoptosis [25]. Moreover,
Lin et al [25] discovered that pterostilbene inhibited prostate
cancer cell growth and proliferation through activation of
AMPK activity and suppression of lipogenesis by decreasing
the expression of fatty acid synthase and acetyl-CoA
carboxylase.
3.4. Colon cancer
The anticarcinogenic effects of pterostilbene have been
demonstrated in various human colorectal carcinoma cells
including Caco-2, COLO 205, HCT-116, and HT-29 cells, and
COLO 205 xenograft tumors [15,28]. Pterostilbene induced
apoptosis by downregulatingmammalian target of rapamycin
(mTOR), phosphatidylinositol 3-kinase (PI3K)/Akt, and
mitogen-activated protein kinases (MAPKs) signaling path-
ways. Pterostilbene also caused autophagy via increasing the
production of Beclin-1 and LC3 II in COLO 205 cells [28]. The
studies conducted by Paul et al [19,63] indicated that pter-
ostilbene inhibited cell proliferation of HT-29 cells by regu-
lating the Wnt/b-catenin-signaling pathway and significantly
reduced the inflammatory regulators. Moreover, in vivo, Chiou
et al [64] suggested that treatment with pterostilbene was able
to inhibit colorectal aberrant crypt foci and colon carcino-
genesis via suppressing the inflammatory signaling regulators
including NF-kB, iNOS, and COX-2 in azoxymethane (AOM)-
induced colonic carcinogenesis in mice. Another research
group demonstrated that pterostilbene could reduce colon
tumor multiplicity and proliferating cell nuclear antigen
(PCNA) and also decreased mucosal levels of the proin-
flammatory cytokines, TNF-a, IL-1b, and IL-4 in AOM-induced
colon carcinogenesis in rats [63].
3.5. Diabetes mellitus
Regarding to antidiabetic activities, pterostilbene was
demonstrated to have cytoprotective effects on pancreatic b-
cell, as it was found to eliminate oxidative stress bymediating
the NF-E2-related factor 2 (Nrf2) downstream target genes
expression including heme oxygenas-1 (HO-1), superoxide
dismutase (SOD), catalase (CAT), and glutathione peroxidase
(GPx) [72]. Also, pterostilbene increased the expression of anti-
apoptotic protein, Bcl-2 and downregulated the proapoptotic
Bax and caspase-3 expression, which protects pancreatic b-
cell from apoptosis in diabetes [72]. Additionally, pterostilbene
significantly lower blood glucose and glycosylated hemoglo-
bin concentration in streptozotocin- and nicotinamide-
induced diabetic rats [66]. Treatment with pterostilbene
significantly increased the expression of glycolysis enzyme,
hexokinase, and decreased the expression of gluconeogenesis
enzymes, glucose-6-phosphatase and fructose-1,6-
bisphosphatase, which regulate glucose homeostasis [66].
Table 2 e The biological activities and molecular effects of pterostilbene.
Modes/treatments Model used Mechanism References
Inflammation
pterostilbene (1e10mM) 3T3-L1 & RAW 264.7 coculture YIL-6 & TNF-a secretion
YCOX-2, YiNOS, YIL-6, YTNF-a,
YPAI-1, YCRP, YMCP-1, Yresistin,
Yleptin,
YMigration ofmacrophages toward
adipocytes
Hsu et al, 2013 [67]
Pterostilbene (0.1e1mM) HUVECs YMonocyte binding, YsICAM1, YIL-
8, YMCP-1, YsE-selectin, Yp-eIF2a,
YICAM1, YMMP9, YCRP78
Liu et al, 2016 [68]
Breast cancer
Pterostilbene (40e80mM) MCF-7 YCell viability, [Apoptosis,
[Caspase-3, [Bax, YBcl-2, [ROS
generation, YMMP, [AMACR
Chakraborty et al, 2010 [69]
Pterostilbene (50e100mM) MCF-7 & Bcap-37 YCell viability, [Apoptosis, [PARP,
[G1 phase arrest, Ycyclin D1, Yb-
catenin, [autophagy, [LC3 II
Wang et al, 2012 [18]
Pterostilbene (15e50mM) MCF-7 [Autophagy, [Beclin 1, [LC3 II,
[ROS generation
Chakraborty et al, 2012 [70]
Prostate cancer
Pterostilbene (1e25mM) LNCaP YCell viability, [G1 phase arrest,
[CDNK1A, [CDNK1B, Yprostate-
specific antigen
Wang et al, 2010 [71]
Pterostilbene (40e80mM) PC-3 [Apoptosis, [caspase-3, [Bax,
YBcl-2, [ROS generation, YMMP,
[AMACR
Chakraborty et al, 2010 [69]
Pterostilbene (40e100mM) LNCaP YCell viability, [G1 phase arrest,
[p53, [p21, [p-AMPK, Yfatty acid
synthase, Yacetyl CoA carboxylase
Lin et al, 2012 [25]
Pterostilbene (40e100mM) PC-3 YCell viability, [apoptosis,
[caspase-3, [Caspase-9, [p-AMPK,
Yfatty acid synthase, Yacetyl CoA
carboxylase
Lin et al, 2012 [25]
Colon cancer
Pterostilbene (1e30mM) HT-29 YCell viability, Ycyclin D1, Yc-Myc,
[PARP, YTNF -a, YIL-1b, YIFN-g,
YiNOS, YCOX-2
Paul et al, 2009 [19]
Pterostilbene (0.004%) AOM-induced colonic
carcinogenesis rat
YTumor multiplicity, YPCNA,
YTNF-a, YIL-1b, YIL-4
Paul et al, 2010 [63]
Pterostilbene (50mM) HT-29 Yb-catenin, Ycyclin D1, Yc-Myc,
YIkBa,Yphosphorylation of p65
Paul et al, 2010 [63]
Pterostilbene (5e100mM) HCT-116, HT-29, & Caco-2 YCell viability, Ycolony formation
capacity, [apoptosis, [caspase-3,
[PARP
Nutakul et al, 2011 [15]
Pterostilbene (50 ppm & 250 ppm) AOM-induced colonic
carcinogenesis mice
YAberrant crypt foci, lymphoid
nodules & tumors, YNF-kB,
YiNOS,YCOX-2, [heme oxygenase-
1, [Glutathione reductase, [Nrf2
Chiou et al, 2011 [79]
Pterostilbene (5e50mM) COLO 205, HCT-116 & HT-29 [Apoptosis, [caspase-3, -8, -9,
YmTOR/p70S6K, YPI3K/Akt,
YMAPKs, Yp-ERK1/2, Yp-JNK1/2,
[autophagy, [LC3 II
Cheng et al, 2014 [28]
Pterostilbene (10 mg/kg BW) COLO 205 xenograft nude mice YTumor volume, Ytumor weight,
YCOX-2, YMMP-9, YVEGF, Ycyclin
D1, [caspase-3
Cheng et al, 2014 [28]
Diabetes
Pterostilbene (40 mg/kg BW) Diabetic rats YBlood glucose, YGlycosylated
hemoglobin, [Hexokinase,
YGlucose-6-phosphatase,
YFructose-1,6-bisphosphatase
Pari et al, 2006 [66]
Pterostilbene (4mM & 8mM) INS-1E (insulin-secreting
rat insulinoma) b-cell line
[Nuclear Nrf2, [HO-1, [CAT,
[SOD, [GPx, [Bcl-2, YBax,
Ycaspase-3
Bhakkiyalakshmi
et al, 2014 [72]
(continued on next page)
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Table 2 e (continued )
Modes/treatments Model used Mechanism References
Pterostilbene (15 mg/kg & 50 mg/kg BW) Wistar rats fed an
obesogenic diet
YHOMA-IR, [GLUT4, [p-Akt/total
Akt ratio, [cardiotrophin-1,
[glucokinase
Gomez-Zorita et al, 2015 [73]
Dyslipidemia
Pterostilbene (40 mg/kg BW) Streptozotocin-nicotinamide
induced type II diabetes rats
YVLDL-C, YLDL-C, [HDL-C,
Ytriglycerides, Yfree fatty acids,
Yphospholipids
Satheesh & Pari, 2008 [74]
Pterostilbene (15 mg/kg & 30 mg/kg BW) Wistar rats fed an
obesogenic diet
Y Adipose tissue weight, Y ME,
YFAS, YG6PDH, YCPT-1a, YACO
Gomez-Zorita et al, 2014 [75]
Pterostilbene (10e50mM) H4IIEC3 cells PPARa ligand, [PPARa gene
expression
Rimando et al, 2015 [76]
Aging
Pterostilbene (0.004% or 0.016%) Aged male Fischer rats
(19-mo-old)
YCognitive behavioral deficits,
Ydopamine release, [pterostilbene
levels in hippocampus, [working
memory
Joseph et al, 2008 [77]
Pterostilbene (120 mg/kg diet) SAMP8 mice YThe number of errors over 2-day
radial arm water maze test,
[MnSOD, [PPAR-a,
Yphosphorylated JNK, YPHF
Chang et al, 2012 [78]
ACO ¼ acetyl-coA carboxylase; AMACR ¼ a-methylacyl-CoA recemase; Bcl-2 ¼ B-cell leukemia/lymphoma 2; CAT ¼ catalase; CDNK1A ¼ cyclin-
dependent kinase inhibitor 1A; CDNK1B ¼ cyclin-dependent kinase inhibitor 1B; COX-2 ¼ cyclooxygenase-2; CPT-1a ¼ carnitine palmitoyl-
transferase 1a; CRP¼ C-reactive protein; FAS¼ fatty acid synthase; G6PDH¼ glucose-6-phosphate dehydrogenase; GLUT4¼ glucose transporter
4; GPx ¼ glutathione peroxidase; HDL-C ¼ high density lipoprotein cholesterol; HO-1 ¼ heme oxygenase-1; HOMA-IR ¼ homeostatic model
assessment-insulin resistance; IFN-g ¼ interferon gamma; IkBa ¼ inhibitor of kappa B; IL-1b ¼ interleukin 1 beta; IL-4 ¼ interleukin 4; IL-6 ¼
interleukin 6; IL-8¼ interleukin 8; iNOS¼ inducible nitric oxide synthase; LC3 II¼ autophagy-related protein light chain 3 II; LDL-C¼ low density
lipoprotein cholesterol; MAPKs ¼mitogen-activated protein kinases; MCP-1 ¼monocyte chemoattractant protein-1; ME ¼malic enzyme; MMP
¼ matrix metallopeptidase; mTOR ¼ mammalian target of rapamycin; Nrf2 ¼ NF-E2-related factor 2; p70S6K ¼ 70 kDa ribosomal protein S6
kinase; PAI-1 ¼ plasminogen activator inhibitor-1; p-AMPK ¼ phosphorylated adenosine monophosphate activated protein kinase; PARP ¼ poly
ADP-ribose polymerase; PCNA ¼ proliferating cell nuclear antigen; p-eIF2a ¼ phospho-eIF2a; p-ERK1/2 ¼ phosphorylated-extracellular signal-
regulated kinase 1/2; PHF ¼ paired helical filaments; PI3K ¼ phosphatidylinositol 3-kinase; p-JNK1/2 ¼ phospho-JNK1/2; sICAM1 ¼ soluble
intercellular adhesionmolecule-1; PPARa ¼ peroxisome proliferator activated receptor alpha; ROS¼ reactive oxygen species; SOD ¼ superoxide
dismutase; TNF-a ¼ tumor necrosis factor-a; VEGF ¼ vascular endothelial growth factor; VLDL-C ¼ very low density lipoprotein cholesterol.
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strated that pterostilbene improved glycemic control. Pter-
ostilbene was shown to decrease insulin resistance index
(HOMA-IR) and increase GLUT4 protein expression,
phosphorylated-Akt/total Akt ratio, cardiotrophin-1, and
glucokinase activity in insulin-resistant rats induced by obe-
sogenic diet [73].
3.6. Dyslipidemia
Dyslipidemia results in various health problems such as
obesity, hypertension, type 2 diabetes, atherosclerosis, and
coronary heart disease. Satheesh and Pari [74] indicated that
pterostilbene could effectively modify the dyslipidemia, as it
can decrease low density lipoprotein cholesterol (LDL-C) and
very low density lipoprotein cholesterol (VLDL-C) and in-
crease the high density lipoprotein cholesterol (HDL-C) in
streptozotocin-nicotinamide induced diabetic rats. In addi-
tion, pterostilbene significantly reduced the levels of serum
and tissue triacylglycerols, free fatty acids, and phospho-
lipids [74]. Moreover, Gomez-Zorita et al [75] evaluated the
hypolipidemic effects of pterostilbene in Wistar rats which
were fed obesogenic diet with or without pterostilbene for 6
weeks. The findings of this study showed that pterostilbene
greatly reduced total adipose tissue weights including peri-
renal, mesenteric, and subcutaneous fat mass. The activitiesof lipogenic enzymes, malic enzyme (ME), fatty acid synthase
(FAS), and acetyl-CoA carboxylase (ACC) were significantly
reduced in white adipose tissue. The glucose-6-phosphate
dehydrogenase (G6PDH) and malic enzyme (ME) involved in
liver lipogenesis were also reduced. Moreover, the activities
of fatty acid oxidation enzymes, carnitine palmitoyl-
transferase 1a (CPT-1a), and acyl-CoA oxidase, were mark-
edly increased in liver. Thus, the proposed mechanisms for
reducing body fat by pterostilbene are reduction of lipogen-
esis in adipose tissue and liver and induction of fatty acid
oxidation in liver.
Furthermore, a recent study by Rimando et al [76] provided
insight that pterostilbene acts as a peroxisome proliferator
activated receptor a (PPARa) ligand, which regulates fatty acid
b-oxidation. Pterostilbene markedly increased PPARa gene
expression in a dose dependent manner in H4IIEC3 rat hepa-
toma cells. Moreover, the activation of PPARa gene expression
of pterostilbene at 10 mmol/L was greater than that of fenofi-
brate at 100 mmol/L and 200 mmol/L, which is a clinical drug
used to treat high cholesterol levels [76]. Thus, dietary pter-
ostilbene may be effective in correcting the dyslipidemia.
3.7. Aging
Recent reports indicate that pterostilbene possesses high po-
tential in bioactivities than its analogue resveratrol. However,
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fects of pterostilbene. A study conducted by Joseph et al [77]
examined the preventive effect of pterostilbene on age-
related behavioral changes in aged rats. Treatment of aged
rats with 0.004% and 0.016% concentration of pterostilbene in
diet improved the cognitive behavioral deficits, as well as
dopamine release, and work memory, which was correlated
with pterostilbene levels in the hippocampus [77]. Moreover,
pterostilbene, but not resveratrol, was demonstrated to
significantly decrease number of errors over a 2-day radial
arm water maze test in SAMP8 mice, a model of accelerated
aging that is increasingly being validated as a model of spo-
radic and age-related Alzheimer’s disease. Pterostilbene also
improved the cellular stress, inflammation, and Alzheimer’s
disease pathology through upregulation of PPAR-a expression,
showing higher modulator potential than resveratrol [78].4. 3′-Hydroxypterostilbene
30-Hydroxypterostilbene (trans-3,5-dimethoxy-30,40-dihydrox-
ystilbene), one of metabolites of pterostilbene [30], can also be
isolated from whole plant of the herb Sphaerophysa salsula, a
shrub widely distributed in central Asia and northwest China
[31]. A recent study indicated that 30-hydroxypterostilbene
possesses anti-adipogenic, -inflammatory, -oxidant, and Sirt-
1 inhibitory activities [79]. However, there is a paucity of
published studies involving biological activities of 30-hydrox-
ypterostilbene (Table 3).4.1. Leukemia
In a study conducted by Tolomeo et al [20], it was reported that
30-hydroxypterostilbene exerted cytotoxicity in five different
human leukemia cell lines (HL60, K562, HUT78, HL60-R, and
K562-ADR) but showed low toxicity in normal hemopoietic
stem cells. The proposed mechanism of antiproliferation po-
tential of 30-hydroxypterostilbene in leukemia cells was due to
intrinsic apoptotic cell death by disrupting mitochondrial
membrane potential [20].Table 3 e The biological activities and molecular effects of 3′-h
Modes/Treatments Model used
Leukemia
30-hydroxypterostilbene
(0.7e5mM)
HL60, K562, HUT78 HL60-R,
K562-ADR
YCell
Ymito
Colon cancer
30-hydroxypterostilbene
(5e50mM)
COLO 205, HCT-116, HT-29 [Apop
YPI3K
[auto
30-hydroxypterostilbene
(10 mg/kg BW)
COLO 205 Xenograft nude mice YTum
YCOX
30-hydroxypterostilbene
(12e50 mg/mL)
HCT-116, MDA-MB-231, PC-3,
HepG2, 3T3-L1, enzyme incubation
YCell
COX-2 ¼ cyclooxygenase-2; LC3 II ¼ autophagy-related protein light chai
metallopeptidase 9; mTOR ¼ mammalian target of rapamycin; p70S6K
extracellular signal-regulated kinase 1/2; PI3K ¼ phosphatidylinositol 3
growth factor.4.2. Colon cancer
Recently, 30-hydroxypterostilbene was demonstrated to have
antiproliferation effects in human colon cancer COLO 205,
HCT-116, and HT-29 cells [28]. The results of the study showed
that 30-hydroxypterostilbene induced apoptosis and auto-
phagy by increasing the activities of caspase-3, -8, and -9 and
inhibiting mTOR/p70S6K, PI3K/Akt, and MAPKs signaling
pathways. In the same study, further experiments were con-
ducted to evaluate the antitumor effect of 30-hydroxypter-
ostilbene in vivo using COLO 205 xenograft nude mice model.
The findings suggested that 30-hydroxypterostilbene signifi-
cantly inhibited the tumor volume and tumor weight via
downregulating the protein expressions of COX-2, MMP-9,
vascular endothelial growth factor (VEGF), and cyclin D1.
Moreover, the anticancer effects of 30-hydroxypterostilbene
were more potent than that of pterostilbene in human colon
cancer cells and xenograft nude mice [28].5. Bioavailability of resveratrol and
pterostilbene
Although resveratrol has been reported to possess many
pharmacological effects, one potential issue surrounding
resveratrol is that resveratrol has low systemic bioavailability
which may lower its effectiveness [14]. Pterostilbene shares
many pharmacological similarities with resveratrol such as
antioxidant, -inflammation, -cancer, -diabetes, and hypolipi-
demic activity [18,19,25,73]; however, pterostilbene exhibits
much better bioavailability and ismore biologically active than
resveratrol [15,19,80]. Based on the chemical structure, pter-
ostilbene could possess better bioavailability as it contains two
extra methoxy groups at the A-phenyl ring of resveratrol. The
two methoxy groups cause pterostilbene to have relatively
higher lipophilicity, which may enhance the cell membrane
permeability and increase its oral absorption [60].
In a study conducted by Nutakul et al [15], it was indicated
that the amount of intracellular pterostilbene was two to four
times higher than those of resveratrol following treatments ofydroxypterostilbene.
Mechanism Reference
proliferation, [apoptosis,
chondrial membrane potential
Tolomeo et al, 2005 [20]
tosis, [caspase-3, -8, -9, YmTOR/p70S6K,
/Akt, YMAPKs, Yp-ERK1/2, Yp-JNK1/2,
phagy, [LC3 II
Cheng et al, 2014 [28]
or volume, Ytumor weight,
-2, YMMP-9, YVEGF, Ycyclin D1,[caspase-3
Cheng et al, 2014 [28]
viability, Yadipogenesis,YSirt-1 Takemoto et al, 2015 [79]
n 3 II; MAPKs ¼ mitogen-activated protein kinases; MMP-9 ¼ matrix
¼ 70 kDa ribosomal protein S6 kinase; p-ERK1/2 ¼ phosphorylated-
-kinase; p-JNK1/2 ¼ phospho-JNK1/2; VEGF ¼ vascular endothelial
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Caco-2, HT-29, and HCT-116 human colon cancer cells [15].
The same study also showed that pterostilbene exhibited
much stronger antiproliferation and apoptotic effects than
those of resveratrol. The IC50 of pterostilbene was two to five
times lower than those of resveratrol in cell viability among
three human colon cancer cells. Intravenous administrations
of resveratrol, pterostilbene and 3,5,40-trimethoxy-trans-stil-
bene (TMS) to rats showed that pterostilbene and TMS had
greater plasma exposure and lower clearances, as well as
longer half-life [81e83]. It was suggested that methoxylation
on hydroxyl groups of pterostilbene or TMS could hinder their
metabolism and appeared to have better pharmacokinetic
characteristics than their natural occurring analog, resvera-
trol [83]. Moreover, Chiou et al [79] demonstrated that pter-
ostilbene was more potent than resveratrol in preventing
colon tumorigenesis via activation of the Nrf2-mediated
antioxidant signaling pathway. Likewise, other research
group indicated that pterostilbene was more effective than
resveratrol as an anti-inflammatory agent for inhibition of
colon carcinogenesis in HT-29 human adenocarcinoma cell
line [19]. Therefore, the biological activities of pterostilbene
were usually found to be more potent than resveratrol might
due to its higher bioavailability.
Biological functions of resveratrol might be somewhat
limited by first-pass metabolism [16]. Accumulating studies
demonstrated that Phase II conjugation, sulfate, and glucu-
ronide conjugates, mainly occur on the hydroxyl groups of
stilbenoid compounds in the body [16,21,84,85], since resver-
atrol containing three hydroxyl groups is rapidly converted to
its glucuronide and sulfate conjugates that lower its
bioavailability. However, in order to further understand
whether the metabolites of resveratrol possess any biological
functions, Mikstis et al [40] evaluated the anticancer activity of
resveratrol and its sulfated conjugates against breast cancer
cell lines. The results of this study showed that the cytotox-
icity of human sulfated metabolites (trans-resveratrol 3-O-
sulfate, trans-resveratrol 40-O-sulfate, and trans-resveratrol 3-
O-40-O-disulfate) were less potent than that of resveratrol. The
cytotoxicity effects of all sulfated metabolites were reduced
about 10 times in comparison with resveratrol against three
different breast cancer cell lines (MCF-7, ZR-75-1 and MDA-
MB-231) [40].
Recent studies showed that the methoxylation on the free
hydroxyl groups of resveratrol could reduce itsmetabolization
and increased its plasma exposure [81,83]. Furthermore, in a
pharmacokinetic study, pterostilbene was shown to have 80%
oral bioavailability in comparison to only 20% for resveratrol
[16]. Thus, the findings of these studies indicated that pter-
ostilbene, dimethyl ether of resveratrol, showedmuch greater
bioavailability than resveratrol.6. Summary
This review provides important evidence that stilbenoid
compounds such as resveratrol, pterostilbene, and 30-
hydroxypterostilbene have promising applications for the
management and treatment of chronic disorders, such asheart disease, stroke, cancer, diabetes, and obesity. Methyl-
ated modification of resveratrol found in pterostilbene and 30-
hydroxypterostilbene appeared to have stronger biological
properties. Low bioavailability might be one of the factors that
affect the bioactivities of resveratrol, while more studies are
required to elucidate the molecular mechanism of their
bioactive actions. Moreover, pterostilbene, dimethyl ether of
resveratrol, exhibits much greater bioavailability and bioac-
tivity than resveratrol, making it an ideal chemopreventive
and chemotherapeutic agent. However, the human studies of
stilbenoid compounds are still lacking, future clinical research
for these compounds in chronic diseases is necessary to
investigate their physiological and pharmacological effects
and safety.Conflicts of interest
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